高コレステロール血症治療ワクチン(PCSK9)の世界市場機会分析...市場調査レポートについてご紹介

【英文タイトル】MarketVIEW: Cholesterol (PCSK9) vaccines - Global vaccine commercial opportunity assessment

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

****This product is composed of two forecast models and a summary presentation
※PAGES: ~90 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Author’s note
Contents
Executive Summary
Commercial model: key model outputs
PCSK9 vaccines: predicted venues by scenario to 2030
PCSK9 vaccines: predicted revenues by region to 2030
PCSK9 vaccines: predicted volume to 2030
Patient numbers: PCSK9 vaccines versus anti-PCSK9 mAbs to 2030
Cardiovascular disease (CVD): background and epidemiology
Cardiovascular disease: a major cause of death
The economic burden of cardiovascular disease (US)
The economic burden of cardiovascular disease (EU)
Secondary causes of hyperlipidemia most commonly encountered in clinical practice
Managing CVD: EU and US lipid guidelines – background
Major changes in new US ATP IV guidelines
Focus on CVD risk groups
CVD risk groups: Heterozygous familial hypercholesterolemia (heFH)
LDL-C treatment goals
LDL-C treatment goals: comparing EU to US
LDL-C treatment goals: ESC/EAS LDL-C treatment targets
LDL-C treatment goals: intervention strategies by risk group/ LDL-C
LDL-C lowering treatments
Statins: lipid lowering intensity levels
Drivers of statin choice
Patient subgroups: statin benefits outweigh risks
Side effects of statins
LDL-C lowering treatment uptake: general
Hospitalized CVD patients discharged on statin therapy, 1996-2006, by EU country
LDL-C lowering treatment uptake: by risk group
LDL-C goal achievement in CVD patients
LDL-C goal achievement in heFH patients
Anti-PCSK9 monoclonal antibodies: Novel LDL-C lowering agents
Background to PCSK9 inhibitors
PCSK9 role in LDL cholesterol (LDL-C) metabolism
PCSK9 inhibition strategies
PCSK9 monoclonal antibodies: current status
Broad target populations for anti-PCSK9 mAbs
PCSK9 monoclonal antibodies: overview of competitor activity
Sanofi Aventis – alirocumab (SAR236553)
Sanofi Aventis – alirocumab: Phase II data
Sanofi Aventis – alirocumab: ODYSSEY program
Sanofi Aventis – alirocumab: Phase III – ODYSSEY results
Submissions of alirocumab (SAR236553) – PraluentTM
PraluentTM – market opportunity (US/EU5/Japan)
Amgen – evolocumab (REPATHATM)
Evolocumab: example Phase III data (TESLA Part B)
Evolocumab: market opportunity (US/EU5/Japan)
Pfizer – bococizumab
Summary of anti-PCSK9 mAbs: outcomes studies
PCSK9 – other targetted therapies
Concerns with anti-PCSK9 monoclonals
Other remaining questions regarding PCSK9 inhibitors
PCSK9 vaccines: background and overview of R&D
PCSK9 vaccine: key model assumptions
The role of a PCSK9 vaccine
PCSK9 vaccine: Target Product Profile (TPP)
PCSK9 vaccine development – AFFiRiS AG
PCSK9 vaccine development – Pfizer
PCSK9 vaccine development – Pfizer (preclinical data)
Pros and cons of PCSK9 vaccine approach
PCSK9 vaccine: modelling commercial potential
Key model inputs: countries & target populations
Key model inputs: vaccine market penetration
Key model inputs: vaccine dosing/pricing
Key model inputs: vaccine discontinuation rate
Key model inputs: summary table
Methodology: definition of risk groups
Modelling methodology
Risk groups modelled
CVD hospital discharges
Death rates CHD
Coronary revascularisation (TCA and CABG combined), hospital discharges
Transluminal coronary angioplasty (TCA) and coronary artery bypass graft (CABG) discharges
Methodology: stroke incidence
Appendix: Anti-PCSK9 monoclonals: List of major clinical trials
ODYSSEY program – overview of Phase III trials
Phase III trials of evolocumab
Phase III trials of bococizumab
Bibliography
About VacZine Analytics
Disclaimer

[Contents – Vaccine demand model TX vaccine (MS Excel-based)]
※Worksheets ~ 35 interconnected

Title sheet
CHARTS – VALUE
CHARTS – VOLUME
CHARTS – TREATED PATIENTS
Vaccine – Value
Vaccine – Volume
Patients – mAbs
Secondary prevention
Country worksheets 
US
Canada
France
Germany
Italy
Spain
UK
Other Europe
Australia
Source material 
Key inputs
Vaccine price summary
Coronary revascularisation
TCA
CABG
PAD
Stroke
US discharge trends
heFH
LDL-C goals
WHO
Statins in CVD patients
Clinical trials
Total population
Back pagenull


【レポート販売概要】

■ タイトル:高コレステロール血症治療ワクチン(PCSK9)の世界市場機会分析
■ 英文:MarketVIEW: Cholesterol (PCSK9) vaccines - Global vaccine commercial opportunity assessment
■ 発行日:2015年2月
■ 調査会社:VacZine Analytics
■ 商品コード:VZINE50201
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。